stockrow
Friday 6 November 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
- EPS
- 0.00%
- Free cash flow
- 0.00%
- Total debt
- +79.3%
Quarter to June 2026, against a year earlier
0.51
0.01
+2.00%
Follow CTOR
Alert me
Citius Oncology, Inc. (CTOR) P/E ratio
Citius Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 305× (August 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 305×
Ten-year median
0.0×
Current reading's percentile
68
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| CTOR Citius Oncology, Inc. | n/m |
| TLPH Talphera, Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| INCR InterCure Ltd. compare | 6.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)